NEW YORK, Feb 15 (Reuters) - Invitae Corp (NVTAQ.PK), opens new tab received court approval on Thursday to run a five-month bankruptcy sale process, allowing the genetic testing company to find a ...

Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...

April 16 (Reuters) - The U.S. Department of Justice's bankruptcy watchdog said on Monday that genetic test maker Invitae Corp should not be allowed to hire Kirkland & Ellis as bankruptcy counsel ...

Invitae is facing two main challenges - assembling a coherent business model from dozens of acquisitions and avoiding a cash crunch looming in 2024/2025. The company has taken decisive action to ...

Invitae (NVTA) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to loss of $0.81 per share a year ago. These figures are adjusted ...

Spotlight Top Pick InVitae Corp (NYSE:NVTA) has seen its stock decline and one culprit was a recently published article “How a cancer test maker started by former Twitter, Google execs hopes to change ...

Invitae has made progress in its business realignment plan, cutting cash burn by one-half from 2022 to 2023. However, the company still faces significant challenges. Invitae shares have lost more than ...

Invitae (NYSE: NVTA) shares have plummeted more than 80% this year. The genetic testing company has grown revenue over the years, but it hasn't been able to turn that revenue into profit. Instead, ...